Latest NxStage Medical Inc. Stories
LAWRENCE, Mass., Jan. 4, 2011 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer and Robert S. Brown, Chief Financial Officer, will present at the 29th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2011 at 11:30 a.m. (PST). The live webcast of NxStage's presentation and accompanying slides will be made available at http://www.nxstage.com/ir.cfm at...
LAWRENCE, Mass., Dec. 20, 2010 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Joseph E. Turk, Jr., has been promoted to the position of President of its North American operations. Reporting to Jeffrey Burbank, Chief Executive Officer of NxStage, Mr. Turk will continue to manage the Company's North American commercial teams across the Company's three markets (Home, Critical Care, and In-Center) and...
LAWRENCE, Mass., Dec. 16, 2010 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that a group of its first patients are celebrating their seven-year anniversary of home hemodialysis treatment with the NxStage® System One(TM), the only hemodialysis machine cleared by the FDA for home use. Each of these patients continues to experience the improved health and quality of life benefits possible with more frequent...
LAWRENCE, Mass., Nov. 30, 2010 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems division has started distributing its in-center products through Metro Medical Supply, Inc., a leading full-service dialysis supplies provider. NxStage has given Metro Medical non-exclusive distribution rights to Medisystems' products, including its premier bloodline, Streamline® and its MasterGuard® and...
LAWRENCE, Mass., Nov. 22, 2010 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today commented on the just- released findings of the Frequent Hemodialysis Network (FHN) Daily Trial that compared in-center hemodialysis administered under a three times per week schedule ("conventional dialysis") versus six shorter sessions per week ("short daily dialysis"). The FHN Daily Trial, published in the New England Journal of Medicine,...
LAWRENCE, Mass., Nov. 17, 2010 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM) today announced the sale of 3.2 million shares of its common stock pursuant to an underwriting agreement with Canaccord Genuity Inc. The closing price of the Company's common stock on the Nasdaq Global Market on November 17, 2010 was $21.38 per share. The Company expects to use the proceeds from the sale of the shares for working capital and general corporate purposes. Closing of the offering is...
LAWRENCE, Mass., Nov. 9, 2010 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer and Robert Brown, Chief Financial Officer, will participate in the following schedule of investor conferences. Jefferies 2010 Boston Healthcare Summit Boston Harbor Hotel Boston, MA Tuesday, November 16, 2010 Lazard Capital Markets 7th Annual Healthcare...
LAWRENCE, Mass., Nov. 4, 2010 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported record financial results for the third quarter of 2010 ended September 30, 2010. Net revenue for the third quarter of 2010 increased to $45.0 million, an increase of 18 percent when compared with revenue of $38.0 million for the third quarter of 2009. Solid performance across the Home and Critical Care markets drove the year...
LAWRENCE, Mass., Nov. 3, 2010 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it has expanded its Medisystems® in-center product portfolio to include Vasc-Alert's automated vascular access surveillance product. Pursuant to the terms of the strategic Agreement with Vasc-Alert LLC, the service can be purchased exclusively from NxStage in the United States. Vasc-Alert, a patented medical device, uses...
LAWRENCE, Mass., Nov. 3, 2010 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it ranked number 53 on Technology Fast 500(TM), Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the period from 2005-2009. NxStage Medical, Inc. grew 2,380...
